hydrochlorothiazide has been researched along with Arteriosclerosis, Coronary in 16 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 9.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions." | 9.17 | Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. ( Bakris, G; Briasoulis, A; Dahlof, B; Hester, A; Hua, T; Jamerson, K; Kelly, RY; Pitt, B; Weber, MA; Zappe, D, 2013) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 6.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 5.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions." | 5.17 | Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. ( Bakris, G; Briasoulis, A; Dahlof, B; Hester, A; Hua, T; Jamerson, K; Kelly, RY; Pitt, B; Weber, MA; Zappe, D, 2013) |
| "We utilized data from 22,576 hypertensive coronary artery disease patients, prospectively enrolled in the INternational VErapamil-Trandolapril STudy (INVEST)." | 5.16 | Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. ( Brumback, BA; Cooper-Dehoff, RM; Delaney, JA; Gerhard, T; Johnson, JA; Pepine, CJ; Shuster, J; Winterstein, AG, 2012) |
| " Statistical modeling from INVEST (INternational VErapamil-Trandolapril STudy), suggests an association between dual and triple therapy and decreased risk of primary outcome ([PO] first occurrence of death, nonfatal MI, or nonfatal stroke) in patients with hypertension and coronary artery disease (CAD)." | 5.12 | Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. ( Bakris, GL; Champion, A; Cooper-Dehoff, RM; Kupfer, S; Pepine, CJ; Zhou, Q, 2007) |
| "We analyzed 5017 Hispanic and 4710 non-Hispanic white hypertensive women with coronary artery disease (CAD) in the INternational VErapamil SR/Trandolapril STudy (INVEST) to determine the impact of baseline characteristics and BP control on CV outcomes." | 5.12 | Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST. ( Cangiano, JL; Cooper-DeHoff, RM; Garcia-Barreto, D; Gaxiola, E; Handberg, E; Pepine, CJ; Zhou, Q, 2007) |
| " The study was designed as a side arm of INSIGHT (International Nifedipine Study: Intervention as Goal for Hypertension Therapy), aimed to show the efficacy of nifedipine once daily versus co-amilozide (hydrochlorothiazide 25 mg, amiloride 2." | 5.09 | Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. ( Motro, M; Shemesh, J, 2001) |
| "The US cohort of the International Verapamil SR-Trandolapril Study (INVEST), a randomized clinical trial of 16 688 patients aged 50 years or older with hypertension and coronary artery disease, was conducted between September 2, 1997, and December 15, 2000, with in-trial follow-up through February 14, 2003." | 4.02 | Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial. ( Cooper-DeHoff, RM; Dasa, O; Gong, Y; Handberg, E; Howard, G; Pepine, CJ; Smith, SM, 2021) |
| "7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a beta-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients." | 3.75 | INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. ( Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q, 2009) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 2.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sarkar, G | 1 |
| Gaikwad, VB | 1 |
| Sharma, A | 1 |
| Halder, SK | 1 |
| Kumar, DA | 1 |
| Anand, J | 1 |
| Agrawal, S | 1 |
| Kumbhar, A | 1 |
| Kinholkar, B | 1 |
| Mathur, R | 1 |
| Doshi, M | 1 |
| Bachani, D | 1 |
| Mehta, S | 1 |
| Dasa, O | 1 |
| Smith, SM | 1 |
| Howard, G | 1 |
| Cooper-DeHoff, RM | 9 |
| Gong, Y | 3 |
| Handberg, E | 2 |
| Pepine, CJ | 10 |
| Bakris, G | 1 |
| Briasoulis, A | 1 |
| Dahlof, B | 1 |
| Jamerson, K | 1 |
| Weber, MA | 1 |
| Kelly, RY | 1 |
| Hester, A | 1 |
| Hua, T | 1 |
| Zappe, D | 1 |
| Pitt, B | 1 |
| Karnes, JH | 1 |
| Pacanowski, MA | 1 |
| McDonough, CW | 1 |
| Arwood, MJ | 1 |
| Langaee, TY | 2 |
| Johnson, JA | 3 |
| Walsh, SN | 1 |
| Kerchner, K | 1 |
| Sangüeza, OP | 1 |
| Bakris, GL | 3 |
| Zhou, Q | 4 |
| Kupfer, S | 2 |
| Champion, A | 3 |
| Handberg, EM | 2 |
| Mancia, G | 2 |
| Legler, UF | 1 |
| Gerhard, T | 1 |
| Delaney, JA | 1 |
| Shuster, J | 1 |
| Brumback, BA | 1 |
| Winterstein, AG | 1 |
| Vandell, AG | 1 |
| Lobmeyer, MT | 1 |
| Gawronski, BE | 1 |
| Gums, JG | 1 |
| Beitelshees, AL | 1 |
| Turner, ST | 1 |
| Chapman, AB | 1 |
| Bailey, KR | 1 |
| Boerwinkle, E | 1 |
| Liggett, SB | 1 |
| Marks, RG | 1 |
| Kowey, P | 1 |
| Messerli, FH | 3 |
| Cangiano, JL | 2 |
| Garcia-Barreto, D | 2 |
| Keltai, M | 1 |
| Erdine, S | 2 |
| Bristol, HA | 1 |
| Kolb, HR | 1 |
| Cohen, JD | 2 |
| Parmley, WW | 1 |
| Flack, JM | 1 |
| Cooper-Dehoff, R | 1 |
| Hewkin, AC | 1 |
| Gaxiola, E | 1 |
| Coca, A | 1 |
| Benetos, A | 1 |
| Motro, M | 1 |
| Shemesh, J | 1 |
| Borhani, NO | 1 |
| Brugger, SB | 1 |
| Byington, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
9 trials available for hydrochlorothiazide and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Artery Disease; | 2022 |
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Coronary Artery Disease; Double-Blind Metho | 2013 |
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Confounding Factors, Epidemiologic; Coronary Artery D | 2012 |
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2003 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Confidence Intervals; Coronary Artery Disease; Femal | 2007 |
Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics.
Topics: Aged; Amiloride; Calcinosis; Calcium Channel Blockers; Cardiomyopathies; Coronary Artery Disease; Di | 2001 |
Multicenter study with isradipine and diuretics against atherosclerosis. US MIDAS Research Group.
Topics: Arteriosclerosis; Calcium Channel Blockers; Carotid Artery Diseases; Coronary Artery Disease; Diuret | 1990 |
7 other studies available for hydrochlorothiazide and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2021 |
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
Topics: Aged; Antihypertensive Agents; Black or African American; Case-Control Studies; Coronary Artery Dise | 2013 |
Challenge. What is your diagnosis? Answer. Primary nodal diffuse large B-cell lymphoma with secondary cutaneous involvement.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; C | 2009 |
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coro | 2009 |
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Bloc | 2012 |
Calcium antagonist strategies for coronary artery disease.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Diastole | 2004 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D | 2008 |